ScholarMate
English简体中文繁體中文
客服熱線:400-1616-289
登入註冊
期刊論文

Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse

Lin, Chuangzhen; Yu, Bingqing; Liu, Xuelian; Chen, Lixin; Zhang, Zhaohui; Ye, Weixiang; Zhong, Hui; Bai, Wenke; Yang, Yuping; Nie, Biao*南方医科大学
Biomedicine and Pharmacotherapy2022-6DOI: 10.1016/j.biopha.2022.112984
2被引18閱讀
引用收藏
分享

摘要

Objective: Obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, is believed to alleviate nonalcoholic fatty liver disease (NAFLD) by decreasing hepatic lipogenesis in an FXR-dependent manner. Here, we revealed a novel mechanism by which OCA improves NAFLD by affecting hepatic long-chain fatty acids (LCFAs) uptake. Methods: Stably transfected HEK-293 cells expressing fatty acid transport protein 5 (FATP5) were established to examine fatty acid uptake; FXR-/-, human (h) FATP5, and FXR-/-/hFATP5 mouse models were incorporated to explore the effects of OCA on FATP5 ex vivo and in vivo. Results: OCA inhibited hFATP5 (IC50 =0.07 mu M) more than murine (m) FATP5 (IC50 =1.04 mu M) as measured by LCFAs uptake in FATP5 expressing HEK-293. OCA also inhibited LCFA uptake in primary hepatocytes from hFATP5 mice, FXR-/-/hFATP5 mice more than that from FXR(-/-)mice, ex vivo. Moreover, OCA inhibited LCFAs uptake by livers in hFATP5 mice and FXR-/-/hFATP5 mice, but not in FXR-/- mice, in vivo. Long-term administration of 0.04% OCA markedly reduced hepatic triglyceride (TG) accumulation in hFATP5 mice and FXR-/-/ hFATP5 mice by 63% and 53%, respectively, but not in FXR-/- mice. Conclusions: OCA ameliorated high-fat diet-induced NAFLD independent of FXR by inhibiting hepatic hFATP5mediated LCFAs uptake. This suggests that the therapeutic effects of OCA on NAFLD in vivo are mediated by a novel, hFATP5 dependent mechanism.

學科與關鍵詞

關鍵詞
Nonalcoholic fatty liver diseaseObeticholic acidFarnesoid X receptorFatty acid transport protein 5Long-chain fatty acids
相關
載入中…
  • Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice
    Lin, Chuangzhen; Yu, Bingqing; Chen, Lixin; Zhang, Zhaohui; Ye, Weixiang; Zhong, Hui; Bai, Wenke; Yang, Yuping; Nie, Biao*Frontiers in Pharmacology, 2022, 13: 880508.被引 5
  • Hepatic-Accumulated Obeticholic Acid and Atorvastatin Self-Assembled Nanocrystals Potentiate Ameliorative Effects in Treatment of Metabolic-Associated Fatty Liver Disease
    Lu, Huanfen; Ban, Zhenglan; Xiao, Kai; Sun, Madi; Liu, Yongbo; Chen, Fangman; Shi, Tongfei; Chen, Li; Shao, Dan*; Zhang, Ming*; Li, Wei*Advanced Science, 2024.
  • Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis
    Cao, Shengtian; Yang, Xinye; Zhang, Zheng; Wu, Junwen; Chi, Bo; Chen, Hong; Yu, Jianghong; Feng, Shanshan; Xu, Yulin; Li, Jing; Zhang, Yingjun; Wang, Xiaojun*; Wang, Yan*European Journal of Medicinal Chemistry, 2022, 230: 114089.被引 9
查看全部 →

發表資訊

論文狀態
公開發表
期刊
Biomedicine and Pharmacotherapy
發表日期
2022-06
卷期
第 150 卷
頁碼
112984
DOI
10.1016/j.biopha.2022.112984
語言
MULTI-LANGUAGE
成果收錄
SCIE
資助標註
Scientific Research Foundation for Returned Scholars of the Ministry of Education of China, China; National Natural Science Foundation of China, China [81471080]

作者

  • L

    Lin, Chuangzhen (第一作者)

  • Y

    Yu, Bingqing

查看全部 10 位作者收起作者
  • L

    Liu, Xuelian

  • C

    Chen, Lixin

  • Z

    Zhang, Zhaohui

  • Y

    Ye, Weixiang

  • Z

    Zhong, Hui

    southern med univ

  • B

    Bai, Wenke

  • Y

    Yang, Yuping

  • N

    Nie, Biao (通訊)

登入解鎖更多功能

  • 收藏這篇,隨時在「我的 · 收藏」找回
  • 認領你的成果,生成推廣素材
  • 關注作者獲取最新成果
  • 加入項目組、協同寫作
註冊 / 登入

產品服務

  • 科研之友
  • 創新城
  • 科創雲

服務支援

  • 幫助中心
  • 隱私政策
  • 服務條款

聯絡方式

線上客服:【】
客服熱線:400-1616-289
電子郵件:support@scholarmate.com

關注或下載科研之友

微信 QR Code
微信公眾號
客戶端下載 QR Code
下載客戶端
科研成果科研人員科研機構科研動態愛瑞思軟件

©2026 深圳市科研之友网络服务有限公司

公安備案圖示粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417